Pediatric Pneumococcal Serotypes in 4 European Countries
Germaine Hanquet1 , Esther Kissling, Asuncion Fenoll, Robert C. George, Agnes Lepoutre, Tinne Lernout, David Tarragó, Emmanuelle Varon, and Jan Verhaegen
Author affiliations: Author affiliations: Scientific Institute of Public Health, Brussels, Belgium (G. Hanquet, E. Kissling, T. Lernout); Belgian Knowledge Centre, Brussels (G. Hanquet); Instituto de Salud Carlos III, Madrid, Spain (A. Fenoll, D. Tarragó,); Health Protection Agency, London, UK (R. George); Institut de Veille Sanitaire, Saint Maurice, France (A. Lepoutre); Hôpital Européen G. Pompidou, Paris, France (E. Varon); Katholieke Universiteit Leuven Pneumococcus Reference Laboratory, Leuven, Belgium (J. Verhaegen)
Figure 6. Incidence of serotype 19A invasive pneumococcal disease in children <5 years of age (black lines) showing breakdown of erythromycin-resistant (blue lines) versus -susceptible (green lines) infections and rate of macrolide use (gold line) in outpatient settings for A) Spain, B) Belgium, and C) France, 1996–2006. *Defined daily doses per 1,000 inhabitants per day.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.